SCHEMBL25834869

SCHEMBL25834869

CC(C)C(=O)CCCCCCCCCCCCCCCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.65
RXFP1 Q9HBX9 1/20 0.65
ALOX5 P09917 3/20 0.57
HDAC1 Q13547 2/20 0.57
HDAC2 Q92769 2/20 0.57
FAAH O00519 4/20 0.56
CES1 P23141 4/20 0.56
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
HDAC3 O15379 1/20 0.53
MAPK1 P28482 1/20 0.53
ADRA1A P35348 1/20 0.53
HDAC4 P56524 1/20 0.53
SLC6A3 Q01959 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19130442 1.00 MAPT (0.65) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL2625206 1.00 MAPT (0.65) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL19130733 1.00 MAPT (0.65) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL19130712 1.00 MAPT (0.65) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL12398374 1.00 MAPT (0.65) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL2440963 0.98 MAPT (0.61) MAPTRXFP1ALOX5HDAC1HDAC2
Phosphonic Acid SCHEMBL9224713 0.94 MAPT (0.57) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL8088735 0.93 HDAC1 (0.62) MAPTRXFP1ALOX5HDAC1HDAC2
SCHEMBL12968018 0.88 HDAC2 (0.60) MAPTRXFP1HDAC1HDAC2
SCHEMBL23085397 0.86 MAPT (0.61) MAPTRXFP1ALOX5HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 MAPT 3973/4885RXFP1 3075/4885ALOX5 2065/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 MAPT 4094/4885RXFP1 1262/4885ALOX5 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.